SAN FRANCISCO–(BUSINESS WIRE)–Hagens Berman, a national shareholder rights law firm, is investigating whether Corcept Therapeutics Inc. (NASDAQ: CORT) misled investorsSAN FRANCISCO–(BUSINESS WIRE)–Hagens Berman, a national shareholder rights law firm, is investigating whether Corcept Therapeutics Inc. (NASDAQ: CORT) misled investors

Hagens Berman Investigating Corcept Therapeutics (CORT): Shares Fall After Report That FDA Warned Against Relacorilant Drug Application Filing

SAN FRANCISCO–(BUSINESS WIRE)–Hagens Berman, a national shareholder rights law firm, is investigating whether Corcept Therapeutics Inc. (NASDAQ: CORT) misled investors about relacorilant’s efficacy and commercial prospects. Corcept is under renewed scrutiny after Reuters reported on Jan. 30, 2026, that the FDA had warned the company “on several occasions” not to submit its application for relacorilant, its proposed treatment for hypercortisolism.

The report sent Corcept shares down, wiping out approximately $3.2 billion in market capitalization since December 2025.

The firm urges investors who suffered significant losses to contact Hagens Berman to learn more about their legal rights.

Key information:

  • Investors who suffered losses are encouraged to report them.
  • Website: www.hbsslaw.com/investor-fraud/cort
  • Email: CORT@hbsslaw.com
  • Phone: 844-916-0895
  • Video: youtube.com/watch?v=vMk3jcOV3Ng

About the Corcept Therapeutics (CORT) Investigation

Corcept promoted relacorilant’s efficacy and commercial potential, repeatedly assuring investors that its new drug application was “progressing toward approval by the end of” 2025. Company management also stated it was “[more] confident than ever” that Corcept was on track to grow its hypercortisolism business from $3 billion to $5 billion in annual revenue within three to five years.

On Dec. 31, 2025, however, Corcept revealed that it had received a complete response letter (CRL) from the FDA stating the agency could not reach a favorable benefit-risk assessment for relacorilant without additional evidence of effectiveness.

Corcept CEO Joseph K. Belanoff, MD, shared “[w]e are surprised and disappointed by this outcome[.]”

On Jan. 30, 2026, Reuters reported that the FDA had issued a corrected CRL dated Jan. 28, 2026, which disclosed that the agency had warned Corcept “on several occasions” not to submit its relacorilant application—apparently contradicting the company’s prior public statements regarding its communications with regulators.

“We’ve expanded our investigation to include whether Corcept misled investors about its FDA communications, in addition to relacorilant’s efficacy and safety,” said Reed Kathrein, Hagens Berman partner leading the investigation. “We are also examining whether the company overstated its hypercortisolism business.”

If you suffered substantial losses, contact Hagens Berman at www.hbsslaw.com/investor-fraud/cort.

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights law firm specializing in complex litigation and corporate accountability. The firm represents investors, whistleblowers, workers, and others harmed by corporate wrongdoing. Hagens Berman has secured $2.9 billion in this area of law. More at hbsslaw.com and @ClassActionLaw.

Contacts

Reed Kathrein, 844-916-0895

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

How do I teach myself real estate? A practical self-study roadmap

How do I teach myself real estate? A practical self-study roadmap

If you want to learn real estate for beginners, a clear, practical roadmap can turn general curiosity into usable skills. This guide from FinancePolice lays out
Share
Coinstats2026/01/31 12:03
USDC Treasury mints 250 million new USDC on Solana

USDC Treasury mints 250 million new USDC on Solana

PANews reported on September 17 that according to Whale Alert , at 23:48 Beijing time, USDC Treasury minted 250 million new USDC (approximately US$250 million) on the Solana blockchain .
Share
PANews2025/09/17 23:51
Whales Dump 200 Million XRP in Just 2 Weeks – Is XRP’s Price on the Verge of Collapse?

Whales Dump 200 Million XRP in Just 2 Weeks – Is XRP’s Price on the Verge of Collapse?

Whales offload 200 million XRP leaving market uncertainty behind. XRP faces potential collapse as whales drive major price shifts. Is XRP’s future in danger after massive sell-off by whales? XRP’s price has been under intense pressure recently as whales reportedly offloaded a staggering 200 million XRP over the past two weeks. This massive sell-off has raised alarms across the cryptocurrency community, as many wonder if the market is on the brink of collapse or just undergoing a temporary correction. According to crypto analyst Ali (@ali_charts), this surge in whale activity correlates directly with the price fluctuations seen in the past few weeks. XRP experienced a sharp spike in late July and early August, but the price quickly reversed as whales began to sell their holdings in large quantities. The increased volume during this period highlights the intensity of the sell-off, leaving many traders to question the future of XRP’s value. Whales have offloaded around 200 million $XRP in the last two weeks! pic.twitter.com/MiSQPpDwZM — Ali (@ali_charts) September 17, 2025 Also Read: Shiba Inu’s Price Is at a Tipping Point: Will It Break or Crash Soon? Can XRP Recover or Is a Bigger Decline Ahead? As the market absorbs the effects of the whale offload, technical indicators suggest that XRP may be facing a period of consolidation. The Relative Strength Index (RSI), currently sitting at 53.05, signals a neutral market stance, indicating that XRP could move in either direction. This leaves traders uncertain whether the XRP will break above its current resistance levels or continue to fall as more whales sell off their holdings. Source: Tradingview Additionally, the Bollinger Bands, suggest that XRP is nearing the upper limits of its range. This often points to a potential slowdown or pullback in price, further raising concerns about the future direction of the XRP. With the price currently around $3.02, many are questioning whether XRP can regain its footing or if it will continue to decline. The Aftermath of Whale Activity: Is XRP’s Future in Danger? Despite the large sell-off, XRP is not yet showing signs of total collapse. However, the market remains fragile, and the price is likely to remain volatile in the coming days. With whales continuing to influence price movements, many investors are watching closely to see if this trend will reverse or intensify. The coming weeks will be critical for determining whether XRP can stabilize or face further declines. The combination of whale offloading and technical indicators suggest that XRP’s price is at a crossroads. Traders and investors alike are waiting for clear signals to determine if the XRP will bounce back or continue its downward trajectory. Also Read: Metaplanet’s Bold Move: $15M U.S. Subsidiary to Supercharge Bitcoin Strategy The post Whales Dump 200 Million XRP in Just 2 Weeks – Is XRP’s Price on the Verge of Collapse? appeared first on 36Crypto.
Share
Coinstats2025/09/17 23:42